Executive Chairman of Kaleido Biosciences and board member of BMS and Alnylam, former CEO of Cubist
Mike Bonney is Executive Chair of Kaleido Biosciences’ Board of Directors. Previously, Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company, and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating and strategic roles, ending his career there as National Business Director.
Bonney also chairs the boards of Alnylam Pharmaceuticals and Magenta Therapeutics. He is a member of a number of other boards, including Celgene Corporation, Sarepta Therapeutics, and Syros Therapeutics. Bonney spends much of his time identifying and mentoring the next generation of life science leaders.
Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). He received his undergraduate degree in economics from Bates College.
Tom Daniel was President, Global Research and Early Development at Celgene Corporation over the last decade, as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and advanced and commercialized innovative medicines in oncology and inflammatory diseases. He previously served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen, and as Senior Vice President of Discovery Research at Immunex Corporation.
Tom is currently Chairman at Vividion Therapeutics, a director at Juno Therapeutics, VIR Biotechnology, Magenta Therapeutics, ImmunsanT and Zafgen. He is a Trustee of Reed College, and serves on the Board of the Alliance for Lupus Research, on the Biomedical Science Advisory Board of Vanderbilt University Medical Center, and is a senior advisor to BlackThorn Therapeutics. A nephrologist and former academic investigator, Tom was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt.
Dr. Daniel earned his medical degree from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed a medical residency at Massachusetts General Hospital.
Lead Director at Adaptive and LabCorp, former Corporate Vice President at Microsoft and Founder/CEO of drugstore.com
As Corporate Vice President of the Microsoft Health Solutions Group, Peter was responsible for driving the company’s strategy to improve healthcare around the world through software innovation. He lead a global organization dedicated to developing, marketing, selling and supporting software solutions designed to improve the quality and efficiency of healthcare delivery and to empower individuals to become more engaged and responsible for their own health and wellness.
Under his leadership, the Health Solutions Group brought two primary software platforms to market: Amalga, a data aggregation platform for hospitals and health systems, and HealthVault, a personal health application platform designed to put individuals in control of their own health information. Both software platforms are designed to unlock the health data traditionally stored in separate information technology systems and make it readily accessible to the people who need it—whether emergency room doctors, primary care physicians, nurses, specialists, patients, or family caregivers—to make more informed care decisions.
Although Neupert began his career in technology, he became immersed in the world of health when he served as president and chief executive officer of drugstore.com Inc. from July 1998 to April 2001, and as chairman of the board of directors through September 2004. He led drugstore.com to become the leading online retail site for health, wellness, beauty and pharmacy products, and received an Ernst & Young Entrepreneur of the Year award for his work. From 2003 to 2005, he served on the President’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology subcommittee and helping to drive the “Revolutionizing Health Care through Information Technology” report, published in June 2004 by PITAC. Neupert was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2009 through 2011.
Neupert holds a master’s degree in business administration from the Tuck School of Business at Dartmouth College and a bachelor’s degree from Colorado College. He is married with four children and lives in the state of Washington.
Former Senior Vice President, Oncology and Genetics, and Chief Medical Officer at UnitedHealth Group
Lee N. Newcomer, MD, MHA, is the former Senior Vice President, UnitedHealthcare with strategic responsibility for Oncology, Genetics and Women’s Health. Prior to rejoining United Health Group (UHG), Dr. Newcomer was a founding executive of Vivius, a consumer directed venture that allowed consumers to create their own personalized health plans. From 1991 to 2000, Dr. Newcomer held a number of positions at UHG, including Chief Medical Officer. His work there emphasized the development of performance measures and incentives to improve clinical care. Prior to joining UHG, he was Medical Director for CIGNA Health Care of Kansas City.
Dr. Newcomer is a board certified medical oncologist; he practiced medical oncology for nine years in Tulsa, Oklahoma and Minneapolis (Park Nicollet Clinic). He is the former Chairman of Park Nicollet Health Services, an integrated system of over 700 physicians and a 400 bed hospital. The group is nationally recognized for its leadership in quality, safety and lean processes. Dr. Newcomer earned a Bachelor of Arts degree in biology from Nebraska Wesleyan University, an MD degree from the University of Nebraska, College of Medicine, and an MS degree in health administration from the University of Wisconsin at Madison. He completed his internship and residency in internal medicine from the University of Nebraska Hospital, and fellowships in medical oncology and administrative medicine from the Yale University School of Medicine and the University of Wisconsin at Madison, respectively.
Under Dr. Newcomer’s leadership, UnitedHealthcare launched a program to test a bundled payment model for oncologists. His work in this area has been published in numerous leading oncology journals and presented at international conferences.